Exclusionary barriers of generic drugs replacing innovative drugs and american breakthrough in practiceJIN Chun-yang1249-1254
Hepatocyte growth factor receptor inhibitor capmatinib for the treatment of non-small cell lung cancerTONG Ying, HUANG Lu, XIONG Chuan-shuang, HONG Yi, XU Yong1255-1259
Overall analysis of new Chinese herbal drug approval and registration in recent yearsHONG Feng, CHU Dan-dan, XU Hui-fang, MA Lin, LI Hao, LIU Wei1260-1265
Selection of teratogenic drugs for reproductive and developmental toxicity test in non-human primatesCUI Yan-jun, TIAN Yi-chao, ZHOU Li, SUN Zu-yue1266-1273
Development of therapeutic drugs for idiopathic pulmonary fibrosisJIANG Qiu-yan, LIANG Qing, GAO Shao-yan, LI Xiao-he, HUANG Hui, ZHOU Hong-gang1274-1281
Research progress in the cardiovascular toxicity of 15 toxic Chinese materia medicaCHEN Zhao-ying, ZHANG Yong1282-1288
Research progress on the renal protective mechanisms of sodium-dependent glucose transporters 2 inhibitors except hypoglycemic effectTANG Ming-juan, LI Ning-xu1289-1295
Interpretation of"the guidelines for inclusion of patient-reported outcomes in clinical trial protocols:the SPIRIT-PRO extension"ZHOU Hui, YAO Mi, CHEN Jie, CHEN Xiao, CHEN Yi-li, CHEN Wei, YUAN Gang1296-1301
Comparative study on the management of pediatric clinical trials between China and AmericaZHONG Yi-ming, ZHANG Tian-yi, GUO Wen1302-1308
Prediction model of the probability of a lead compound becoming a drug based on Stacked AutoEncoder and Fully Connected Neural NetworkPAN Lei, NI Bing-wei, ZHAO Hong-ping1309-1315